- Home
- CVAC vs PX Comparison
CVAC vs PX Comparison
Compare CVAC & PX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVAC
- PX
- Stock Information
- Founded
- CVAC 2000
- PX 1992
- Country
- CVAC Germany
- PX United States
- Employees
- CVAC N/A
- PX N/A
- Industry
- CVAC Biotechnology: Pharmaceutical Preparations
- PX Investment Managers
- Sector
- CVAC Health Care
- PX Finance
- Exchange
- CVAC Nasdaq
- PX Nasdaq
- Market Cap
- CVAC 1.2B
- PX 1.0B
- IPO Year
- CVAC 2020
- PX 2021
- Fundamental
- Price
- CVAC $5.41
- PX $11.65
- Analyst Decision
- CVAC Hold
- PX Buy
- Analyst Count
- CVAC 3
- PX 8
- Target Price
- CVAC $6.83
- PX $14.19
- AVG Volume (30 Days)
- CVAC 974.1K
- PX 1.1M
- Earning Date
- CVAC 08-14-2025
- PX 08-07-2025
- Dividend Yield
- CVAC N/A
- PX 1.28%
- EPS Growth
- CVAC N/A
- PX N/A
- EPS
- CVAC 0.87
- PX 0.16
- Revenue
- CVAC $566,039,775.00
- PX $298,000,000.00
- Revenue This Year
- CVAC N/A
- PX $1.88
- Revenue Next Year
- CVAC $24.04
- PX $17.29
- P/E Ratio
- CVAC $6.24
- PX $71.92
- Revenue Growth
- CVAC 787.60
- PX 18.92
- 52 Week Low
- CVAC $2.37
- PX $8.57
- 52 Week High
- CVAC $5.72
- PX $14.28
- Technical
- Relative Strength Index (RSI)
- CVAC 59.79
- PX 71.42
- Support Level
- CVAC $5.42
- PX $10.76
- Resistance Level
- CVAC $5.49
- PX $11.07
- Average True Range (ATR)
- CVAC 0.07
- PX 0.31
- MACD
- CVAC -0.06
- PX 0.19
- Stochastic Oscillator
- CVAC 36.67
- PX 99.76
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
About PX P10 Inc.
P10 Inc is a player in the alternative asset management sector, specializing in multi-asset class private market solutions. It offers a range of investment solutions, including specialized funds, separate accounts, secondary investments, direct investments, and co-investments across various asset classes and geographies. These solutions cater to diverse investor needs within the private markets, aiming to deliver superior risk-adjusted returns. With a focus on middle and lower-middle markets, the company's portfolio includes Private Equity, Venture Capital, Impact Investing, and Private Credit. Its Revenue primarily comes from recurring management and advisory fees earned on committed capital, typically locked up for ten to fifteen years.